The LETMD1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B-lymphocyte cell line, engineered for targeted disruption of the LETMD1 gene. This product provides a heterogeneous pool of cells carrying diverse loss-of-function mutations in LETMD1, enabling robust functional evaluation of gene ablation in a lymphoma context. The knockout model is generated without selection for single-cell clonality, preserving polyclonal knockout diversity and avoiding clonal artifacts. It serves as a genetically defined tool for investigating LETMD1-dependent pathways in apoptosis and survival signaling.
The Raji host cell line originates from a Burkitt’s lymphoma patient and is a suspension-based, EBV-positive B-lymphocyte model. These cells are maintained in suspension culture, retain features of antibody-producing B cells, and are widely utilized to study B-cell lymphomagenesis, immune signaling, and therapeutic responses. The Raji background supports high transfection efficiency and robust proliferation, making it well-suited for CRISPR-mediated genome editing and subsequent functional assays.
LETMD1 (also known as HCCR-1) encodes a mitochondrial outer membrane protein that functions as a negative regulator of apoptosis. The protein directly binds and sequesters p53, inhibiting its pro-apoptotic transcriptional activity and blocking downstream events such as cytochrome c release and caspase-9/3 activation. Concurrently, LETMD1 promotes cell survival through activation of the NF-??B pathway, upregulating anti-apoptotic targets including BCL2, XIAP, and survivin. Upstream regulators of LETMD1 include NF-??B, STAT3, and PI3K/Akt signaling, forming feedback loops with p53. At the mitochondrial level, LETMD1 stabilizes membrane potential and interacts with HSP70, further suppressing BAX/BAK-mediated apoptosis. These interactions position LETMD1 at a crucial junction between p53 and NF-??B networks.
In the Raji B-cell lymphoma context, LETMD1 knockout disrupts endogenous survival mechanisms, making these cells a powerful tool for dissecting apoptosis resistance in B-cell malignancies. The model facilitates investigation of p53-independent survival pathways and crosstalk between mitochondrial dysfunction and NF-??B signaling, both relevant to EBV-driven lymphomagenesis. As LETMD1 overexpression has been linked to multiple cancers, this knockout system also supports research into broader oncogenic mechanisms, including those in cervical, breast, colorectal, and hepatocellular carcinomas. It is particularly suitable for studying the interplay between LETMD1 and its interacting partners HSP70 and p53 in a disease-relevant background.
Researchers can apply this polyclonal knockout population in various assays: Western blotting for cleaved caspases and PARP, RT-qPCR for BCL2, XIAP, and survivin, flow cytometry-based Annexin V/PI apoptosis assays, JC-1 mitochondrial membrane potential measurements, co-immunoprecipitation of LETMD1-p53, drug sensitivity testing with etoposide or cisplatin, NF-??B reporter assays, and CellTiter-Glo proliferation assays. These experiments enable detailed mechanistic dissection of LETMD1 function, drug target validation, and screening of apoptosis-modulating compounds in B-cell lymphoma. For additional product information, contact Ascent Research.
